Afatinib: Added benefit in certain mutations confirmed
Thursday, August 20, 2015 - 14:30
in Health & Medicine
In advanced non-small cell lung cancer, the new tyrosine-kinase inhibitor is more effective than combination chemotherapy in patients with certain mutations, reviewers report.
